Home › Funds › GordonMD Global Investments LP › CRNX
GordonMD Global Investments LP position in CRNX
CRINETICS PHARMACEUTICALS IN
GordonMD Global Investments LP reported holding 126,985 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$4.8M, representing 2.30% of its reported portfolio and ranking #15 among its reported holdings. GordonMD Global Investments LP has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GordonMD Global Investments LP's CRNX position evolved
GordonMD Global Investments LP first disclosed a stake in CRNX in Q4 2025 at 224,135 shares (US$10.4M). Across 3 filings, GordonMD Global Investments LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 126,985 shares valued at US$4.8M. Notable position changes include a 43% trim in Q1 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 224.13K | $10.43M | New |
| Q1 2026 | 126.98K | $4.61M | Reduce |
| Q2 2026 | 126.98K | $4.75M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on GordonMD Global Investments LP
FAQ
How long has GordonMD Global Investments LP held CRNX?
GordonMD Global Investments LP has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is GordonMD Global Investments LP's current position in CRNX?
As of Q2 2026, GordonMD Global Investments LP holds 126.98K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $4.75M, representing 2.30% of its reported portfolio and ranking #15.
Has GordonMD Global Investments LP been buying or selling CRNX?
In the latest 13F filing (Q2 2026), GordonMD Global Investments LP held unchanged its position in CRNX.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.